title: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
abstract: In a multicenter study the authors prospectively investigated neurocognitive function in childhood ALL patients. Sixty-six patients (mean age at diagnosis 7.9 +/- 3.6 years, 34 female), treated with repeated intrathecal and systemical methotrexate administrations without cranial irradiation, underwent psychometric testing for intelligence, concentration, and visual-motor integration postdiagnosis and after reinduction therapy. Although there was a statistically significant decline of intellectual function after reinduction therapy for younger patients and girls (IQ scores still within normative data range), there were no differences in visual-motor performance and concentration over the time of induction therapy. Thus, neurocognitive examination should focus on younger ALL patients and girls.
authors: Department of Pediatric Hematology and Oncology, University Hospital for Children and Adolescents. Erlangen. Germany.
authors: Paul
authors: P
authors: Krappmann
authors: Marios
authors: M
authors: Paulides
authors: Wolfgang
authors: W
authors: Stöhr
authors: Edith
authors: E
authors: Ittner
authors: Bernhard
authors: B
authors: Plattig
authors: Petra
authors: P
authors: Nickel
authors: Herwig
authors: H
authors: Lackner
authors: Martin
authors: M
authors: Schrappe
authors: Gritta
authors: G
authors: Janka
authors: Jörn D
authors: JD
authors: Beck
authors: Thorsten
authors: T
authors: Langer
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003072:Cognition Disorders / Q000139:chemically induced* / Q000503:physiopathology; D016371:Cranial Irradiation; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007278:Injections, Spinal; D007361:Intelligence Tests; D008137:Longitudinal Studies; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D003630:Daunorubicin